In 2025, 2% of all manuscripts sent for peer review were submitted using the guaranteed peer review benefit. These manuscripts were high quality, with an acceptance rate above 50%, showing that the ...
You do not currently have access to this content.
Abstract:. In updated phase I clinical trial results, patients treated with zoldonrasib, a KRASG12D-selective inhibitor under study in non–small cell lung cancer, showed an objective response rate of ...
Abstract. Integrin αvβ6 (ITGB6) is a heterodimer located on epithelial cell surfaces, upregulated during epithelial-mesenchymal transition (EMT), and overexpressed in various solid tumors, which is ...
Cancer Res (2026) 86 (8_Supplement): CT184.
Annual Meeting 2026 AACR Journals Simultaneous Publications | American Association for Cancer Research AACR Annual Meeting 2026: AACR Journals’ Simultaneous Publications These AACR journal articles ...
Abstract. Results from the DRUP trial suggest that off-label targeted cancer therapies produce meaningful benefit primarily in tumors with well-validated biomarkers, such as MSI-H, echoing findings ...
Cancer Res (2026) 86 (7_Supplement): 5810.
Cancer Res (2026) 86 (5_Supplement_2): B004.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results